EUVIMEDEUVIMED entdecken
Leitlinie

Symptom‐Based Testosterone Therapy in Japanese Men With Late‐Onset Hypogonadism Syndrome: A Real‐World Single‐Arm Study Following the 2022 Guideline

Yoshikazu Sato iD, Keigo Akagashi, Musashi Tobe iD, Kazunori Haga iD, Kosuke Uchida, Ichiya Honma, Megumi Hirobe, Junji Ishizaki, Takashi Shimizu, Keitarou Watanabe, Hisao Nakajima

International Journal of Urology · 2026

DOI: 10.1111/iju.70257 ↗

Kurz gefasst

Leitlinie in der Zeitschrift International Journal of Urology, 2026. Verfasst von Yoshikazu Sato und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Sanjukai Urological Hospital, Sapporo, Japan. Hauptthemen laut MEDLINE: Testosterone, Hormone Replacement Therapy, Hypogonadism, Phosphodiesterase 5 Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 29 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Following the 2022 revision of the Japanese clinical practice guidelines for late‐onset hypogonadism, more flexible diagnostic criteria have been recommended, emphasizing both clinical symptoms and testosterone levels. This study aimed to evaluate the clinical characteristics of late‐onset hypogonadism syndrome and the effectiveness of testosterone replacement therapy combined with daily phosphodiesterase‐5 inhibitors in symptomatic men, including those with normal testosterone levels.

Methods

From 2019 to 2023, 704 men presenting with late‐onset hypogonadism‐related symptoms were assessed for serum testosterone levels and symptom profiles. Of these, 227 received combination therapy with testosterone replacement therapy and daily phosphodiesterase‐5 inhibitors. Changes in mood, vitality, sexual function and lower urinary tract symptoms were evaluated using validated questionnaires.

Results

The most frequent symptoms were depressive mood, loss of energy, and easy fatigue, which may represent core features of late‐onset hypogonadism syndrome. No significant association was found between testosterone levels and symptom severity. Combination therapy significantly improved symptom scores, as well as subjective feelings of vigor, confidence, and masculinity. Among the patients, 48.4% reported feeling “better” or “much better,” 47.2% reported feeling “slightly better,” and 4.4% experienced “no change” or “worsening.” Patients with normal testosterone levels showed greater improvement in symptom scores. Recovery of morning erections independently predicted overall improvement.

Conclusions

Testosterone replacement therapy combined with daily phosphodiesterase‐5 inhibitors is effective for late‐onset hypogonadism‐related symptoms, even in patients with normal testosterone levels. These findings support the revised Japanese guidelines, which promote a symptom‐oriented treatment strategy alongside biochemical evaluation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TestosteroneHormone Replacement TherapyHypogonadismPhosphodiesterase 5 InhibitorsHumansMaleMiddle AgedJapanAgedPractice Guidelines as TopicTreatment OutcomeDrug Therapy, CombinationLower Urinary Tract SymptomsAge of OnsetAdultEast Asian People

Stichwörter der Autor:innen

hypogonadismmiddle‐agedmorning erectionphosphodiesterase 5 inhibitorstestosterone

Substanzen

TestosteronePhosphodiesterase 5 Inhibitors

Autor:innen und Institutionen

  • Department of Urology, Sanjukai Urological Hospital, Sapporo, Japan.

ORCID-Profile: Yoshikazu Sato, Musashi Tobe, Kazunori Haga

Zitieren

APA

Sato, Y., Akagashi, K., Tobe, M., Haga, K., Uchida, K., Honma, I., Hirobe, M., Ishizaki, J., Shimizu, T., Watanabe, K., & Nakajima, H. (2026). Symptom‐Based Testosterone Therapy in Japanese Men With Late‐Onset Hypogonadism Syndrome: A Real‐World Single‐Arm Study Following the 2022 Guideline. International Journal of Urology. https://doi.org/10.1111/iju.70257

Vancouver

Sato Y, Akagashi K, Tobe M, Haga K, Uchida K, Honma I, et al. Symptom‐Based Testosterone Therapy in Japanese Men With Late‐Onset Hypogonadism Syndrome: A Real‐World Single‐Arm Study Following the 2022 Guideline. International Journal of Urology. 2026. doi:10.1111/iju.70257

BibTeX
@article{Sato2026,
  author = {Sato, Yoshikazu and Akagashi, Keigo and Tobe, Musashi and Haga, Kazunori and Uchida, Kosuke and Honma, Ichiya and Hirobe, Megumi and Ishizaki, Junji and Shimizu, Takashi and Watanabe, Keitarou and Nakajima, Hisao},
  title = {Symptom‐Based Testosterone Therapy in Japanese Men With Late‐Onset Hypogonadism Syndrome: A Real‐World Single‐Arm Study Following the 2022 Guideline},
  journal = {International Journal of Urology},
  year = {2026},
  doi = {10.1111/iju.70257}
}
Kostenlos starten →